- Price
- $34.69
- Day
- -5.19%
- Mkt Cap
- $29.33B
- 52W Range
- $32.49 – $50.88
- Volume
- 7.21M
- Beta
- -0.41
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Nykredit A S Acquires New Holdings in Medline $MDLN
Nykredit A S purchased a new stake in Medline (NASDAQ: MDLN) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 36,116 shares of the company's stock, valued at approximately $1,424,000. A number of other hedge funds and
Kaplan Fox Urges Medline Inc. (MDLN) Investors to Contact the Firm About Possible Securities Law Violations
New York, New York--(Newsfile Corp. - September 8, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may CLICK HERE to contact us.
H&F Corporate Investors X Ltd. Sells 15,599,171 Shares of Medline $MDLN
H&F Corporate Investors X Ltd. reduced its position in shares of Medline (NASDAQ: MDLN) by 18.0% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 70,874,326 shares of the company's stock after selling 15,599,171 shares during the period. Medline comprises
Kaplan Fox & Kilsheimer LLP Alerts Investors of Medline Inc. (MDLN) to an Investigation of Potential Securities Law Violations
New York, New York--(Newsfile Corp. - September 4, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may CLICK HERE to contact us.
Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
NORTHFIELD, Ill., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that Jim Boyle, chief executive officer, and Mike Drazin, chief financial officer, are scheduled to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY, on Tuesday, September 15, 2026, at 12:20pm ET.